Adlai Nortye ANL
NASDAQ ANL
$15.01 +0.26 (+1.76%)
At close: Sep 4, 2026 · 4:00 PM EDT

Adlai Nortye (ANL) Total Non-Current Liabilities (2022 - 2026)

Adlai Nortye (ANL) posted quarterly Total Non-Current Liabilities of $1.1 million for Q4 2025, up 165.18% year-over-year from $425000.0 in Q4 2024, and up 338.52% quarter-over-quarter from $257000.0 in Q2 2025.

Analysis

Adlai Nortye (ANL) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends

Adlai Nortye (ANL) has reported Total Non-Current Liabilities for 4 consecutive years, with $1.1 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Total Non-Current Liabilities rose 165.18% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $1.1 million (up 165.18% YoY), while the FY2025 annual figure was $1.1 million, up 165.18% from the prior year.
  • Total Non-Current Liabilities improved to $1.1 million in Q4 2025 per ANL's latest filing, from $257000.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $5.5 million in Q4 2023 and bottomed at $257000.0 in Q2 2025.
  • Historically, Total Non-Current Liabilities has averaged $1.7 million across 4 years, with a median of $1.1 million in 2025.
  • Annual changes were most pronounced in 2023 — Total Non-Current Liabilities surged 342.48% — and 2024, when it sank 92.23%.
  • Adlai Nortye's Total Non-Current Liabilities stood at $1.2 million in 2022, then soared by 342.48% to $5.5 million in 2023, then tumbled by 92.23% to $425000.0 in 2024, then surged by 165.18% to $1.1 million in 2025.
  • Business Quant data shows ANL's Total Non-Current Liabilities at $1.1 million in Q4 2025, $257000.0 in Q2 2025, and $425000.0 in Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 3.92 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 1.53 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.88 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 4.20 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.32 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.17 Bn
10 Adlai Nortye 500.08 Mn 268.19 Mn - 8.31 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 8.31 Mn
Dec 31, 2025 1.13 Mn
Jun 30, 2025 257,000.00
Dec 31, 2024 425,000.00
Dec 31, 2023 5.47 Mn
Dec 31, 2022 1.24 Mn